Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever
1 other identifier
observational
75
0 countries
N/A
Brief Summary
The soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) was an established biomarker useful for infection in non-neutropenic patients. In this study, we tested sTREM-1 in the patients with neutropenic fever. Pro-calcitonin (PCT) and C-reactive protein (CRP) were also measured. We planned to investigate and explore the role of sTREM-1 in early diagnosis of infection in patients with neutropenic fever.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2008
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2009
CompletedFirst Submitted
Initial submission to the registry
December 16, 2009
CompletedFirst Posted
Study publicly available on registry
December 17, 2009
CompletedDecember 17, 2009
December 1, 2009
8 months
December 16, 2009
December 16, 2009
Conditions
Eligibility Criteria
Patients with hematological malignancy developing neutropenic fever after chemotherapy
You may qualify if:
- chemotherapy-related neutropenia (granulocytes \< 0.5 × 109/l or leukocytes \< 1 × 109/l) and fever (body temperature \> 38.0°C over a 6 hour observation period or body temperature ≥ 38.5°C once.
You may not qualify if:
- prolonged fever before presenting for admission,
- antibiotics therapy in the past 72 hours,
- more than two sites of infectious focus,
- concomitant solid organ malignancy and blast in hemogram.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
whole blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Szu-Chun Hsu, MD
Department of Laboratory Medicine, National Taiwan University Hospital and College of Medicine, Taipei
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 16, 2009
First Posted
December 17, 2009
Study Start
October 1, 2008
Primary Completion
June 1, 2009
Study Completion
June 1, 2009
Last Updated
December 17, 2009
Record last verified: 2009-12